These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
403 related articles for article (PubMed ID: 24884773)
1. Whole brain radiotherapy plus simultaneous in-field boost with image guided intensity-modulated radiotherapy for brain metastases of non-small cell lung cancer. Zhou L; Liu J; Xue J; Xu Y; Gong Y; Deng L; Wang S; Zhong R; Ding Z; Lu Y Radiat Oncol; 2014 May; 9():117. PubMed ID: 24884773 [TBL] [Abstract][Full Text] [Related]
2. Whole-brain radiotherapy plus sequential or simultaneous integrated boost for the treatment of a limited number of brain metastases in non-small cell lung cancer: A single-institution study. Qing D; Zhao B; Zhou YC; Zhu HL; Ma DY Cancer Med; 2020 Jan; 9(1):238-246. PubMed ID: 31749325 [TBL] [Abstract][Full Text] [Related]
3. Hippocampal avoidance with volumetric modulated arc therapy in melanoma brain metastases - the first Australian experience. Awad R; Fogarty G; Hong A; Kelly P; Ng D; Santos D; Haydu L Radiat Oncol; 2013 Mar; 8():62. PubMed ID: 23497418 [TBL] [Abstract][Full Text] [Related]
4. Therapeutic effect of osimertinib plus cranial radiotherapy compared to osimertinib alone in NSCLC patients with EGFR-activating mutations and brain metastases: a retrospective study. Zhai X; Li W; Li J; Jia W; Jing W; Tian Y; Xu S; Li Y; Zhu H; Yu J Radiat Oncol; 2021 Dec; 16(1):233. PubMed ID: 34865626 [TBL] [Abstract][Full Text] [Related]
5. Sparing the hippocampus and the hypothalamic- pituitary region during whole brain radiotherapy: a volumetric modulated arc therapy planning study. Mehta P; Janssen S; Fahlbusch FB; Schmid SM; Gebauer J; Cremers F; Ziemann C; Tartz M; Rades D BMC Cancer; 2020 Jun; 20(1):610. PubMed ID: 32605648 [TBL] [Abstract][Full Text] [Related]
6. Chemoradiotherapy by intensity-modulated radiation therapy with simultaneous integrated boost in locally advanced or oligometastatic non-small-cell lung cancer-a two center experience. Mantel F; Müller E; Kleine P; Zimmermann M; Exner F; Richter A; Weick S; Ströhle S; Polat B; Höcht S; Flentje M Strahlenther Onkol; 2021 May; 197(5):405-415. PubMed ID: 33725133 [TBL] [Abstract][Full Text] [Related]
7. Prognostic factors for survival and radiation necrosis after stereotactic radiosurgery alone or in combination with whole brain radiation therapy for 1-3 cerebral metastases. Schüttrumpf LH; Niyazi M; Nachbichler SB; Manapov F; Jansen N; Siefert A; Belka C Radiat Oncol; 2014 May; 9():105. PubMed ID: 24885624 [TBL] [Abstract][Full Text] [Related]
8. Comparison of efficacy and safety between simultaneous integrated boost intensity-modulated radiotherapy and conventional intensity-modulated radiotherapy in locally advanced non-small-cell lung cancer: a retrospective study. Wang D; Bi N; Zhang T; Zhou Z; Xiao Z; Liang J; Chen D; Hui Z; Lv J; Wang X; Wang X; Deng L; Wang W; Wang J; Wang C; Lu X; Xu K; Wu L; Xue W; Feng Q; Wang L Radiat Oncol; 2019 Jun; 14(1):106. PubMed ID: 31196118 [TBL] [Abstract][Full Text] [Related]
9. Adding simultaneous integrated boost to whole brain radiation therapy improved intracranial tumour control and minimize radiation-induced brain injury risk for the treatment of brain metastases. Zhang K; Zhang T; Guo Z; Zhao F; Li J; Li Y; Li Y; Wu X; Chen X; Zhang W; Pang Q; Wang P BMC Cancer; 2023 Dec; 23(1):1240. PubMed ID: 38104068 [TBL] [Abstract][Full Text] [Related]
10. Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced non-small cell lung cancer in Chinese population: A retrospective study. Xu Y; Zheng X; Bai X; Li P; Ma H; Wang J; Hu X; Chen M Oncotarget; 2017 Jul; 8(30):49084-49092. PubMed ID: 28467775 [TBL] [Abstract][Full Text] [Related]
11. Prospective study of special stage II (T2b-3N0M0) non-small-cell lung cancer treated with hypofractionated-simultaneous integrated boost-intensity modulated radiation therapy. Zhang W; Liu C; Lin H; Song Y; Huang W; Li H; Li M; Li B J Cancer Res Ther; 2015; 11(2):381-7. PubMed ID: 26148604 [TBL] [Abstract][Full Text] [Related]
12. Biological implications of whole-brain radiotherapy versus stereotactic radiosurgery of multiple brain metastases. Xue J; Kubicek GJ; Grimm J; LaCouture T; Chen Y; Goldman HW; Yorke E J Neurosurg; 2014 Dec; 121 Suppl():60-8. PubMed ID: 25434938 [TBL] [Abstract][Full Text] [Related]
13. Clinical outcomes of gastrointestinal brain metastases treated with radiotherapy. Sanghvi SM; Lischalk JW; Cai L; Collins S; Nair M; Collins B; Unger K Radiat Oncol; 2017 Feb; 12(1):43. PubMed ID: 28245881 [TBL] [Abstract][Full Text] [Related]
14. Whole brain radiation therapy plus focal boost may be a suitable strategy for brain metastases in SCLC patients: a multi-center study. Ni M; Jiang A; Liu W; Sheng Y; Zeng H; Liu N; Gao Q; Wang Y; Yu J; Yuan S Radiat Oncol; 2020 Mar; 15(1):70. PubMed ID: 32213185 [TBL] [Abstract][Full Text] [Related]
15. Early experience with hippocampal avoidance whole brain radiation therapy and simultaneous integrated boost for brain metastases. Lebow ES; Hwang WL; Zieminski S; Wang Y; Niemierko A; Mehan WA; Oh KS; Khandekar M; Willers H; Shih HA J Neurooncol; 2020 May; 148(1):81-88. PubMed ID: 32307637 [TBL] [Abstract][Full Text] [Related]